NCT06561321 - Study to Evaluate the Safety and Efficacy of Tapinarof in Adults With Palmoplantar Keratoderma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 30, 2024

Primary Completion Date

February 1, 2026

Study Completion Date

November 1, 2026

Conditions

Palmoplantar Keratoderma

Interventions

DRUG

Tapinarof

Daily topical Tapinarof use will stop disease advancement and improve the quality of life in patients with palmoplantar keratoderma, through its AhR \& NRF2 agonism properties.

Trial Locations (1)

46202

RECRUITING

Indiana University Department of Dermatology, Indianapolis